REGENERON PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $78.1B
- as of Sep 30, 2026
- Shares Outstanding
- 103.0M
- Free Float
- 92.6%
Income Statement
- Revenue
- $14.3B
- Operating Income
- $3.6B
- Net Income
- $4.5B
- EBITDA
- $4.1B
- Revenue Growth, 3Y
- 5.6%
- FCF Margin, 3Y Avg
- 27.9%
- FCF Margin, Worst Year
- 25.8%
Cash Flow
- Free Cash Flow
- $4.1B
- FCF Yield
- 5.2%
- Owner FCF Yield
- 4.0%
Balance Sheet
- Cash & Equivalents
- $3.1B
Returns & Capital
- Dividends Paid
- $370.3M
- Dividend Yield
- 0.5%
- Dividend Payout, 3Y Avg
- 2.7%
- Share Repurchases
- $3.4B
- Buyback Yield, 3Y Avg
- 3.5%
- SBC, 3Y Avg
- $953.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $14.3B | $4.1B | 28.4% |
| FY2024 | $14.2B | $3.7B | 25.8% |
| FY2023 | $13.1B | $3.9B | 29.5% |
| FY2022 | $12.2B | $4.4B | 36.3% |
| FY2021 | $16.1B | $6.5B | 40.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Delta and PepsiCo lower earnings outlooks as revenue rises
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back